JP2024513247A5 - - Google Patents
Info
- Publication number
- JP2024513247A5 JP2024513247A5 JP2023561333A JP2023561333A JP2024513247A5 JP 2024513247 A5 JP2024513247 A5 JP 2024513247A5 JP 2023561333 A JP2023561333 A JP 2023561333A JP 2023561333 A JP2023561333 A JP 2023561333A JP 2024513247 A5 JP2024513247 A5 JP 2024513247A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- pembrolizumab
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172299P | 2021-04-08 | 2021-04-08 | |
| US63/172,299 | 2021-04-08 | ||
| PCT/US2022/023250 WO2022216580A1 (en) | 2021-04-08 | 2022-04-04 | Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513247A JP2024513247A (ja) | 2024-03-22 |
| JP2024513247A5 true JP2024513247A5 (enExample) | 2024-05-28 |
Family
ID=83546458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561333A Pending JP2024513247A (ja) | 2021-04-08 | 2022-04-04 | 抗ｐｄ－１抗体の皮下投与によるがんの治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20250074983A1 (enExample) |
| EP (1) | EP4320163A4 (enExample) |
| JP (1) | JP2024513247A (enExample) |
| KR (1) | KR20230170029A (enExample) |
| CN (1) | CN117279952A (enExample) |
| AR (1) | AR125296A1 (enExample) |
| AU (1) | AU2022254960A1 (enExample) |
| BR (1) | BR112023020867A2 (enExample) |
| CA (1) | CA3214617A1 (enExample) |
| CL (1) | CL2023002976A1 (enExample) |
| CO (1) | CO2023013273A2 (enExample) |
| CR (1) | CR20230473A (enExample) |
| DO (1) | DOP2023000216A (enExample) |
| EC (1) | ECSP23076276A (enExample) |
| GE (1) | GEAP202416385A (enExample) |
| IL (1) | IL307430A (enExample) |
| JO (1) | JOP20230243A1 (enExample) |
| MX (1) | MX2023011857A (enExample) |
| PE (1) | PE20240051A1 (enExample) |
| TW (1) | TW202305009A (enExample) |
| WO (1) | WO2022216580A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102650991B1 (ko) | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| WO2025140467A1 (zh) * | 2023-12-29 | 2025-07-03 | 上海复宏汉霖生物技术股份有限公司 | 稳定的高浓度抗pd-1抗体药物制剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| WO2018223182A1 (en) * | 2017-06-05 | 2018-12-13 | The Council Of The Queensland Institute Of Medical Research | A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor. |
| JP2021513540A (ja) * | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF |
| KR102650991B1 (ko) * | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
-
2022
- 2022-04-01 TW TW111112795A patent/TW202305009A/zh unknown
- 2022-04-04 US US18/554,213 patent/US20250074983A1/en active Pending
- 2022-04-04 WO PCT/US2022/023250 patent/WO2022216580A1/en not_active Ceased
- 2022-04-04 EP EP22785209.2A patent/EP4320163A4/en active Pending
- 2022-04-04 JP JP2023561333A patent/JP2024513247A/ja active Pending
- 2022-04-04 IL IL307430A patent/IL307430A/en unknown
- 2022-04-04 CA CA3214617A patent/CA3214617A1/en active Pending
- 2022-04-04 CN CN202280033638.8A patent/CN117279952A/zh active Pending
- 2022-04-04 GE GEAP202416385A patent/GEAP202416385A/en unknown
- 2022-04-04 BR BR112023020867A patent/BR112023020867A2/pt unknown
- 2022-04-04 AR ARP220100836A patent/AR125296A1/es unknown
- 2022-04-04 PE PE2023002821A patent/PE20240051A1/es unknown
- 2022-04-04 AU AU2022254960A patent/AU2022254960A1/en active Pending
- 2022-04-04 MX MX2023011857A patent/MX2023011857A/es unknown
- 2022-04-04 KR KR1020237038583A patent/KR20230170029A/ko active Pending
- 2022-04-04 CR CR20230473A patent/CR20230473A/es unknown
-
2023
- 2023-10-04 CL CL2023002976A patent/CL2023002976A1/es unknown
- 2023-10-05 DO DO2023000216A patent/DOP2023000216A/es unknown
- 2023-10-05 CO CONC2023/0013273A patent/CO2023013273A2/es unknown
- 2023-10-06 EC ECSENADI202376276A patent/ECSP23076276A/es unknown
- 2023-10-08 JO JOJO/P/2023/0243A patent/JOP20230243A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer | |
| JP5765634B2 (ja) | 低酸素活性化型プロドラッグを用いるがんの処置 | |
| JP2019532051A5 (enExample) | ||
| EP3524268A1 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
| JP2019517549A5 (enExample) | ||
| JP2011511072A5 (enExample) | ||
| JP2012506448A5 (enExample) | ||
| US9205098B2 (en) | Anti-cancer therapies | |
| JP2024513247A5 (enExample) | ||
| JP2020505425A5 (enExample) | ||
| RU2018126829A (ru) | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием | |
| JP2023539589A5 (enExample) | ||
| JP2022527334A5 (enExample) | ||
| JP2019038797A5 (enExample) | ||
| Nie et al. | An exploration of Trifluridine/Tipiracil monotherapy and in combination with bevacizumab or immune checkpoint inhibitors for patients with metastatic colorectal cancer: A Real-World study | |
| IL307430A (en) | Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies | |
| JP2021529777A5 (enExample) | ||
| JP2021523096A5 (enExample) | ||
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| JP2023531090A5 (enExample) | ||
| JP2025504278A5 (enExample) | ||
| JP2005508323A5 (enExample) | ||
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| JP2024515879A5 (enExample) | ||
| Turkington et al. | A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma |